Physician profile
Leora Carter
NPI 1164076378
$2,411.61
in general payments reported to CMS, 2019-2025
9 companies · $1,100 in 2025
The $1,100 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $210 · 2022: $140 · 2023: $262 · 2024: $700 · 2025: $1,100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,062.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,061.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $848.52 | 2024-2025 | Repatha, Evenity, Repatha |
| Astrazeneca Pharmaceuticals LP | $512.32 | 2021-2024 | Farxiga, Tezspire, Lokelma |
| Abbott Laboratories | $268.46 | 2022-2025 | Freestyle Libre 3 |
| Baxter Healthcare | $196.58 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Galderma Laboratories, L.P. | $130.41 | 2025 | Nemluvio |
| Genzyme Corporation | $125.00 | 2024 | |
| Astellas Pharma US INC | $122.79 | 2024 | Veozah |
| Madrigal Pharmaceuticals | $122.24 | 2025 | Rezdiffra |
| Abbvie INC. | $85.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leora Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.